The economics of pharmacotherapy for diabetes mellitus

PharmacoEconomics

Volumn 11, Issue 2, 1997, Pages 139-158

  Costa, Bernardo ^a,b,d   Arroyo, Jaume ^c   Sabaté, Angels ^a  

^a Primary Healthcare   (Spain)

^b Hospital Comarcal Mora d'Ebre   (Spain)

^c Unitat de Medicina Tropical I Salut Internacional Drassanes   (Spain)

^d NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BUFORMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE; GLUCAGON; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; TOLBUTAMIDE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH ECONOMICS; HEALTH EDUCATION; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0031028344     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711020-00004     Document Type: Review

References (124)

1. Committee on Professional Practice. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1989; 12: 365-8
2. Krans HMJ, Porta M, Keen H. Diabetes care and research in Europe: the St. Vincent Declaration Action Programme. Implementation document. G Ital Diabetol 1992; 12 Suppl. 2: 1-56
3. Piwernetz K, Home PD, Snorgaard O, et al. for the DiabCare monitoring group of the Saint Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabet Med 1993; 10: 371-7
4. Leese B. Diabetes Mellitus and the St Vincent Declaration: the economic implications. Pharmacoeconomics 1995; 7: 292-307
5. Aro SA, Kangas T, Reunanen A, et al. Hospital use among diabetic patients and the general population. Diabetes Care 1994; 17: 1320-9
6. Deeb LC, Tan MH, Alberti KGGM. Insulin availability among International Diabetes Federation member associations. Diabetes Care 1994; 17: 220-3
7. Alberti KGGM. Insulin dependent diabetes mellitus: a lethal disease in the developing world: some patients are dying for lack of insulin. BMJ 1994; 309: 754-5
8. Chale SS, Swai ABM, Mujinja PGM, et al. Must diabetes be a fatal disease in Africa? Study of cost of treatment. BMJ 1992; 304: 1215-8
9. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long term complications in IDDM. N Engl J Med 1993; 329: 977-86
10. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 1993; 16: 1517-20
11. Palumbo PJ. DCCT: the continuing challenge ahead. Mayo Clin Proc 1993; 68: 1126-7
12. Lasker RD. The DCCT: implications for policy and practice. N Engl J Med 1993; 329: 1035-6
13. Home PD. Diagnosing the undiagnosed with diabetes. BMJ 1994; 308: 611-2
14. Rubin JR, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78: 809A-F
15. Currie CJ, Peters RJ. Trends in the volume and cost of prescribing for diabetes. Br J Med Econ 1995; 8: 1-9
16. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991; 14: 461-9
17. Horton ES. NIDDM: the devastating disease. Diabetes Res Clin Prac 1995; 28: S3-11
18. Espinosa C, Hart W, Rovira J, et al. El coste de la incidencia de la diabetes mellitus tipo I en España. Endocrinología 1995; 42 Suppl. 1: 22
19. Stern Z, Levy R. The direct cost of type 1 diabetes mellitus in Israel. Diabet Med 1994; 11: 528-33
20. Eisenbarth GS, Verge CF, Allen H, et al. The design of trials for prevention of IDDM. Diabetes 1993; 42: 941-7
21. Clinical practice recommendations of the American Diabetes Association. Position statement: insulin administration. Diabetes Care 1991; 14 Suppl. 2: 30-3
22. Leese B. The cost of diabetes and its complications. Soc Sci Med 1992; 35: 1303-10
23. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57
24. Feldman HI, Strom BL. Utilization of drugs for diabetes mellitus. Drug Saf 1991; 6: 220-9
25. Klein BE, Davis MD, Segal P, et al. Diabetic retinopathy: assessment of severity and progression. Oftalmologia 1984; 91: 10-7
26. Kohner EM. Diabetic retinopathy. In: Mogensen CE, Standl E, editors. Prevention and treatment of diabetic late complications. New York: De Gruyter, 1989: 75-91
27. Costa B, Huguet M, y el Grup per a l'Estudi de la Diabetis a Tarragona (GEDT). Consumo de medicación en la diabetes mellitus (IV): utilización de material reactivo y sistemas para asesorar el control glucémico desde la atención primaria. Med Clin (Barc) 1994; 102: 321-4
28. Assal JP, Muhlhauser I, Pernet A, et al. Patient education as the basis for diabetes care in clinical practice. Diabetologia 1985; 28: 602-13
29. Singh BM, Prescott JJW, Guy R, et al. Effect of advertising on awareness of symptoms of diabetes among the general public: the British Diabetic Association Study. BMJ 1994; 308: 632-6
30. Melander A, Bitzén PO, Faber O, et al. Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72
31. Kaku K, Inoue Y, Kaneko T. Extrapancreatic effects of sulfonylurea drugs. Diab Res Clin Prac 1995; 28: S105-8
32. Lebovitz HE, Melander A. Sulphonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. London: John Wiley & Sons Ltd., 1992: 745-72
33. Wahlyn-Boll E, Melander A, Sartor G, et al. Influence of food intake on the absorption and effect of glipizide in diabetes and healthy in subjects. Eur J Clin Pharmacol 1980; 18: 279-83
34. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54
35. Seltzer HS. Drug-induced hypoglycemia: a review based on 473 cases. Diabetes 1972; 21: 955-66
36. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203-8
37. Nuttall FQ. Dietary fiber in the management of diabetes. Diabetes 1993; 42: 503-8
38. United Kingdom Prospective Diabetes Study Group (UKPDS). Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin-dependent diabetes mellitus followed for three years. BMJ 1995; 310: 83-8
39. Herman LS, Melander A. Biguanides: basics aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. London: John Wiley & Sons Ltd., 1992: 773-95
40. Golay A, Guillet-Dauphiné N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabet Metab Rev 1995; 11: 63-7
41. Bailey CJ. Metformin and intestinal glucose handling. Diabet Metab Rev 1995; 11: S23-32
42. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
43. Costa B, Acarbosa y diabetes. ¿ Modesta mejoría o auténtico avance terapéutico? Med Clin (Barc) 1995; 105: 341-3
44. American Diabetes Association. Self-monitoring of blood glucose. Diabetes Care 1995; 18: 408-13
45. Pickup JC, Crook MA, Tutt P. Blood glucose and glycated haemoglobin measurement in hospital: which method? Diabet Med 1993; 10: 402-10
46. King H, Dowd JE. Primary prevention of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 3-8
47. Wolf AM, Colditz GA. The cost of obesity. Pharmacoeconomics 1994; 5 Suppl. 1: 34-7
48. Sheehan JP, Ulchaker MM. Early pharmacotherapy in non-insulin-dependent diabetes mellitus. Arch Intern Med 1991; 151: 198-201
49. Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990; 150: 803-6
50. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med 1988; 5: 275-81
51. Alberti KGMM, Gries FA, Jervell J, et al. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabet Med 1994; 11: 899-909
52. Laporte JR, Porta M, Capella D. Drug utilization studies: a tool for determining the effectiveness of drug use. Br J Clin Pharmacol 1983; 16: 301-30
53. Bergman U, Sjqvist F. Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Med Scand 1984; Suppl. 683; 15-20
54. World Health Organization. Anatomical Therapeutic Chemical Classification index including DDDs for plain substance (ATC Index). Upssala: WHO Technical Reports, 1991; 14
55. Costa B, Utgés P, Monclús JF, et al., y el Grup per a l'Estudi de la Diabetis a Tarragona (GEDT). Consumo de niedicación en la diabetes mellitus (I). Estimación del perfil terapéutico y la prevalencia en Tarragona. Med Clin (Barc) 1992; 99: 294-9
56. García-Iñesta A. Estudios de utilización de medicamentos en España y análisis de la situación farmacoterapéutica. In: Estudios de utilización de medicamentos, editor. Instituto Nacional de la Salud. Madrid: Ruan SA, 1988; 17-48
57. Reeves ML, Seingler DE, Ryan EA. Glycemic control in insulin dependent diabetes mellitus: comparison of outpatient intensified conventional therapy with continous subcutaneous insulin infusion. Am J Med 1982; 72: 673-80
58. Williams DDR, Munroe C, Haspedales CJ, et al. A three-year evaluation of the quality of diabetes care in the Norwich Community Care Schema. Diabet Med 1990; 7: 74-9
59. Figuerola D, Castell C, Lloveras G. La diabetes en España: análisis de la prevalencia y atención médica según consumo de fármacos y material de autocontrol. Med Clin (Barc) 1989; 91: 401-5
60. Costa B, Belmonte M. Cost implications of wastage of drugs: focus on insulin. Pharmacoeconomics 1994; 6: 1-4
61. Costa B, Hernández JM, y el Grup per a l'Estudi de la Diabetis a Tarragona GEDT. Consumo de medicación en la diabetes mellitus (III). Tendencias de uso y consumo de medicación hipoglucemiante en Tarragona, Cataluña y España (1988-1991). Med Clin (Barc) 1993; 100: 571-5
62. Stika L. Patterns in drug utilization. National and international aspects: antidiabetic drugs. Acta Med Scand 1984; Suppl. 683; 53-7
63. Kennedy DL, Piper JM, Baum C. Trends in use of oral hypoglycaemic agents 1964-1986. Diabetes Care 1988; 11: 558-62
64. Papoz L, Vauzelle F, Vexiau P, et al. Pattern of treatment among diabetic patients in France. Diabetes Care 1988; 11: 586-691
65. Goday A, Serrano-Ríos M. Epidemiología de la diabetes mellitus tipo I en España: revisión crítica y nuevas perspectivas. Med Clin (Barc) 1994; 102: 306-15
66. Bergman U, Elmes P, Hale M, et al. The measurement of drug consumption: drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 1975; 8: 83-9
67. Stanulovic M, Jakovljevic V, Kovac T, et al. Regional and international comparison in utilization of antidiabetic drugs. Int J Clin Pharmacol Ther Toxicol 1986; 24: 254-6
68. University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes: mortality results. Diabetes 1970; 19 Suppl. 2: 785-830
69. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22
70. Leibowitz G, Cersi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996; 39: 503-14
71. Carpenter MA, Bodansky HJ. Drug treatment of obesity in type 2 diabetes mellitus. Diabet Med 1990; 7: 99-104
72. Berne C, Agenäs I, Eriksson G, et al. Insulin wastage in ambulant practice. Diabetes Care 1984; 7: 343-6
73. Costa B, Monclús JF, Huguet M, y el Grup per a l'Estudi de la Diabetis a Tarragon a (GEDT). Consumo de medicación en la diabetes mellitus (II): utilización y pérdida de insulina: interés epidemiológico y socioeconómico. Med Clin (Barc) 1993; 100: 241-4
74. Berger M, Köbberling J, Windeler J. Workshop report. Appraisal of effectiveness and potential therapeutic benefit of acarbose: a non-consensus conference. Diabetologia 1996; 39: 873-4
75. Houtzagers CMGJ, Berntzen PA, Van der Stap H, et al. Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med 1989; 6: 416-21
76. Kronsbein P, Jörgens V, Mülhauser I, et al. Evaluation on a treatment and education structured program for non-insulin dependent diabetes mellitus. Lancet 1988; II: 1407-10
77. Greendyke RM, Cost analysis: bedside blood glucose testing. Am J Clin Pathol 1992; 97: 106-7
78. Lewandrowski EL, Laposata M, Eschenbach K, et al. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. Am J Med 1994; 97: 222-30
79. Jörgens V. Cost-benefit analysis of teaching and care programs in Type 2 diabetes. Diabete Metab 1993; 19: 510-3
80. Isackson D, Stalhammar J. Prescription drug use among diabetics: a population study. J Chronic Dis 1987; 40: 651-60
81. Lebrun T, Marissal JP. Socioeconomic consequences of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1995; 11: S87-95
82. Rendell M, Lassek WD, Ross DA, et al. A pharmaceutical profile of diabetic patients. J Chronic Dis 1983; 36: 193-202
83. Harris MI, Cowie C, Eastman R. Health-insurance coverage for adults with diabetes in the US population. Diabetes Care 1994; 17: 585-91
84. Mazze RS. A systems approach to diabetes care. Diabetes Care 1994; 17 Suppl. 1: 5-11
85. Olsson J, Tollin C, Persson U, et al. Diabetes mellitus: comparisons of prevalence and antidiabetic drug utilisation and of treatment costs and costs of production losses due to morbidity. Post Marketing Surveillance 1993; 7 (Spec. Iss.): 240-1
86. Olsson J, Persson U, Tollin C, et al. Comparison of excess costs of care and production losses because of morbidity in diabetic patients. Diabetes Care 1994; 17: 1257-63
87. Passa PH, Giraud S. Cost of antihypertensive treatment in diabetic patients. Diabete Metab 1993; 19: 523-7
88. Espinosa C, Hart W, Roviera J, et al. El coste de la diabetes mellitus en España en 1994. Av Diabetol 1996; 12: 31
89. Chantelau E. Diabetes treatment in developing countries. Lancet 1993; 342: 620
90. Teuscher A, Kiln MR. Patient-empowerment and free insulin market. Lancet 1994; 344: 1299-300
91. Jorgensen KD, Hanssen KF, Mosand R, et al. The 'insulin pen': comparison with multiple injection treatment with syringe. Pract Diab 1986; 3: 90-1
92. Van Gaal L, Krzentowski G, Rottiers R, et al. Passage de l'insuline U-40 à l'insuline U-100: l'expérience belge. Practical aspects of U-100 insulin conversion in Belgium. Diabete Metab 1992; 18: 317-21
93. Lekkerkerker JF. A changeover to U100 insulin in The Netherlands? Neth J Med 1987; 31: 191-9
94. Costa B, Estopá A, Borrás J, et al. Diabetes y farmacoeconomía. Eficiencia de los sistemas disponibles para la inyección de insulina en España. Atención Primaria 1995; 16: 391-6
95. Costa B, Estopá A, Borrás J, et al. Consumo de medicación en la diabetes mellitus (V). Farmacoeconomía y aceptación de la conversión hospitalaria a insulina U100. Med Clin (Barc) 1996; 106: 481-5
96. Dunbar JM, Madden PM, Gleeson DT, et al. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994; 17: 874-8
97. Rob HK, Boëthius G, Bergman U. Insulin use according to change in concentration and pack size in a population-based drug database in Jämtland, Sweden. Pharmacoepidemiol Drug Saf 1994; 3: 94
98. Arroyo J. Estudi d'utilització de medicació hipoglicemiant a l'Area de Gestió 7, Centre de l'Institut Català de la Salut (1986-1990) [thesis]. Barcelona: University of Barcelona, 1993
99. Holmes B, Heel RC, Brogden RN, et al. Gliclazide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 1984; 27: 301-27
100. Alexis GA, Henault R, Sparr HB. Conversion from glipizide to glyburide: a prospective cost-impact survey. Clin Ther 1992; 14: 409-17
101. Noyes MA, Carter BL, Helling DK, et al. Evaluation of glipizide and glyburide in a health maintenance organization. Ann Pharmacother 1992; 26: 1215-20
102. Alexis G, Henault R, Sparr HB. Conversion from glipizide to glyburide: long-term follow-up of a cost-impact survey focusing on the elderly. Clin Ther 1993; 15: 607-15
103. Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomised, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes melitus. Ann Intern Med 1996; 124: 136-45
104. Wolever TM, Singer W, Chiasson JL, et al. Acarbose improves abnormal insulin metabolism in type 2 diabetes. Clin Res 1993; 41: A360
105. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-64
106. Mason B, Matsuyama J, Jue S. Adherence consistency across treatment regimens. Diabetes Care 1994; 17: 347-8
107. Tjoa HI, Kaplan NM. Non pharmacological treatment of hypertension in diabetes mellitus. Diabetes Care 1991; 4: 449-60
108. Vlcek J, Tesarova M, Fendrich Z. Analysis of pharmacotherapy of hypertension in out-patients. Pharm World Sci 1995; 17: 81-6
109. Breyer JA, Hunsicker LG, Bain RP, et al., and the Collaborative Study Group. Angiotensin converting enzyme inhibition in diabetic nephropaty. Kidney Int 1994; 45 Suppl. 45: S156-160
110. Bojestig MB, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-8
111. Borch-Johnsen K. The economics of screening for microalbuminuria in patients with insulin-dependent diabetes mellitus. Pharmacoeconomics 1994; 5: 357-60
112. Llor C, Vila A, Alvarez M, et al. Anàlisi de la despesa farmacèutica i estalvi potencial en la prescripció de fàrmacs antihipertensius. Salut Catalunya 1995; 9: 90-4
113. Peters AL, Davidson MB, Ziel F. Cost-effective screening for diabetic retinophaty using a nonmydriatic retinal camera in a prepaid health-care setting. Diabetes Care 1993; 16: 1193-5
114. American Diabetes Association. Screening for diabetic retinopathy. Diabetes Care 1993; 16 Suppl. 2: 16-8
115. Gries F. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Diab Res Clin Pract 1995; 28 Suppl.: S201-7
116. Diabetes Integrated Care Evaluation Team. Integrated care for diabetes: clinical, psychosocial, and economic evaluation. BMJ 1994; 308: 1208-12
117. Copeland RJ, Fuller S, Howard P, et al. Developing therapeutic monitoring criteria for ward pharmacists. Pharm J 1995; 254: 629-31
118. Siddons H. The cost of education. Diabet Med 1994; 11: 239-40
119. Starfield B, Powe NR, Weiner JR, et al. Cost vs quality in different types of primary care settings. JAMA 1994; 272: 1903-8
120. Davidson JK. Assessment of program effectiveness at Grady Memorial Hospital. In: Laurence P. Steinert G, editors. Edueating of the diabetic patient. New York: Springer Publishing Co., 1981: 309-16
121. Fore WW. Reimbursement for diabetes self-care training: the North Carolina experience. Diabetes Care 1994; 17: 608-10
122. Heise T, Bucher E, Heinemann L, et al. Waste of money in diabetes treatment. Diabetologia 1994; 37 Suppl. 1: A27
123. Gruesser M, Bott U, Ellermann P, et al. Evaluation of a structured treatment and teaching program for non-insulin-treated type 11 diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16: 1268-75.
124. Arroyo J. Acarbose Today Symposium. Conseil Assessor sobre la Diabetis a Catalynya. Associació Catalana de Diabetis. Barcelona, Spain. 6 Nov, 1995